Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

(2016) Jérôme Boursier et al.   JOURNAL OF HEPATOLOGY

Critical comparison of elastography methods to assess chronic liver disease

(2016) Mireen Friedrich-Rust et al.   Nature Reviews Gastroenterology & Hepatology

Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B

(2015) M. Houot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Assessment of liver fibrosis: The relationship between point shear wave elastography and quantitative histological analysis

(2015) Hong Ding et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards

(2015) Jérôme Boursier et al.   JOURNAL OF HEPATOLOGY

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

(2015)   JOURNAL OF HEPATOLOGY

Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort

(2015) Julia Kälsch et al.   Scientific Reports

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity

(2015) Thierry Poynard et al.   BMJ Open

Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia

(2014) H. Perazzo et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis

(2014) D. T. Chao et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

(2014) Pierre Bedossa et al.   HEPATOLOGY

Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)

(2014) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

(2013) Roger Chou et al.   ANNALS OF INTERNAL MEDICINE

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

(2013) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis

(2012) Thierry Poynard et al.   Clinical Gastroenterology and Hepatology

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

(2012) Pierre Bedossa et al.   HEPATOLOGY

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population

(2012) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data

(2012) Thierry Poynard et al.   PLoS One

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases

(2011) G. Sebastiani et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

(2011) Thierry Poynard et al.   BMC GASTROENTEROLOGY

Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity

(2011) Guillaume Lassailly et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease

(2011) Leon A Adams et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate

(2011) Thierry Poynard et al.   Clinics and Research in Hepatology and Gastroenterology

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

(2010) Thierry Poynard et al.   BMC GASTROENTEROLOGY

ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure

(2010) T. Poynard et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited

(2008) J. Lambert et al.   CLINICAL CHEMISTRY

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease

(2008) Sylvie Naveau et al.   HEPATOLOGY